ArticleFoods (Basel, Switzerland)2025
Xylose-Oligosaccharide Alleviating Type 2 Diabetes in Mice via Reducing Blood Glucose, Oxidative Stress, Inflammation and Regulating Intestinal Microbiota.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Type 2 diabetes, a widespread metabolic disorder, is characterized by hyperglycemia and insulin resistance. Xylose-oligosaccharide, a functional oligosaccharide, has shown potential in mitigating hyperglycemia. This study established a type 2 diabetes mouse model via a high-fat diet and streptozotocin administration to investigate the effects of two xylose-oligosaccharide doses (20 and 60 mg/kg/day). Both doses were observed to regulate lipid metabolism, decrease inflammation, and alleviate damage to the liver, kidneys, and islets. Additionally, xylose-oligosaccharide corrected diabetes-induced intestinal microbiota imbalances by increasing Bacteroides and Proteobacteria while decreasing Firmicutes. Notably, the 60 mg/kg/day dose was more effective in enhancing glucose tolerance and reducing insulin resistance compared to the 20 mg/kg/day dose. These results suggested that xylose-oligosaccharide had hypoglycemic effects, reduced insulin resistance and oxidative stress, possessed anti-inflammatory properties, and modulated intestinal microbiota. Thus, xylose-oligosaccharide shows promise as a functional food for managing type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.